Göran Gannedahl

Pharmaceutical Product Development LLC engages in the operation of a global contract research organization, which provides drug development, laboratory and lifecycle management services. It offers adaptive trial design, bio analytical lab, bio similar development, biostatistics, GMP lab, clinical supplies, trial monitoring, CMC regulatory, data management, dental pain clinic, real-world outcomes, site intelligence and activation, central lab, global regulatory affairs, IRT systems, late stage research, medical communications, device and diagnostics, medical writing, nonclinical development and regulatory consulting and intelligence, regulatory development, innovation and vaccine sciences. The company was founded by Fredric N. Eshelman in 1985 and is headquartered in Wilmington, NC.

Ancoria Insurance Ltd. provides insurance services. It offers life insurance policies and occupational pension schemes. The company was founded by Sievert Larsson in 1987 and is headquartered in Nicosia, Cyprus.

MIVAC Development AB develops treatment of autoimmune diseases and mucosal vaccine. The company was founded in 2008 and is headquartered in Goteborg, Sweden.

Entreprenörskapital i Sverige AB provides activities of securities and commodity brokers. It attracts companies to support companies in a start-up phase. It is the products of the collective wealth of risk capital experience. It desires to explore new approaches to investing in unlisted companies. It delivers benefits to investors, entrepreneurs, customers, and society. The company was founded by Raymond Peter Wendel on January 12, 2011 and is headquartered in Gothenburg, Sweden.

Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022.

F.A Management AB is a private company that provides corporate consulting services. The CEO of the Swedish company is Fredrik Andersson.

Sinfonia Biotherapeutics AB is a Swedish clinical stage company that develops biologics for neuropathic pain. The private company is based in Huddinge, Sweden.

Founded in 1992, Theradex (Europe) Ltd. is a subsidiary of Theradex Systems, Inc. that engages in research and experimental development on biotechnology. The company is based in Crawley, UK.

Inorbit Therapeutics AB discovers and develops small molecule therapeutics based on molecules with proven clinical efficacy in humans. The company was founded in 2015 and is headquartered in Moelndal, Sweden.

Ivarsson Medical Research AB is a Swedish company that engages in the management and trading of securities. The CEO of the private company is Marie-Lois Ivarsson.

RGNT Electric AB is a Swedish company that specializes in electric motorcycles. The company is based in Kungsbacka, Sweden. The company's range of motorbikes is both timeless and forward-thinking. RGNT Electric was founded in 2019 by Jonathan Åström. Göran Karlsson has been the CEO of the company since January 12, 2023.

Part of Link Medical Research AS, Link Medical Research AB is a company that provides product development services for the pharmaceutical and medical device industries. The company is based in Solna, Sweden. The Swedish company was founded in 1995 by Ola Gudmundsen. Ola Gudmundsen has been the CEO since 1995.

Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients.